MRNA
Moderna Delivers Strong Q1 2026 Performance: Revenue Growth, Cost Reduction, and Pipeline Advancements
Moderna, a leading biotechnology company, reported a remarkable first quarter of 2026, showcasing significant revenue growth, cost reduction efforts, and notable advancements in its pipeline. The company's revenues surged to $0.4 billion year-over-year, primarily driven by the execution of its long-term strategic partnership with the U.K.